Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma

A prospective, randomized phase II study, with mandatory tumor sampling at current disease stage, aimed to identify biomarkers predictive of improved progression-free survival (PFS) in patients with pancreatic cancer treated with erlotinib. Patients with histologically/cytologically confirmed, unres...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2014-07, Vol.25 (7), p.1384-1390
Hauptverfasser:	Propper, D., Davidenko, I., Bridgewater, J., Kupcinskas, L., Fittipaldo, A., Hillenbach, C., Klughammer, B., Ducreux, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over biomarkers Biomarkers, Tumor - metabolism erlotinib Erlotinib Hydrochloride Female Humans Male Middle Aged pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism personalized therapy Placebos predictive markers Prospective Studies Protein Kinase Inhibitors - metabolism Protein Kinase Inhibitors - therapeutic use Quinazolines - metabolism Quinazolines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!